Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Hims & Hers Health the Best Growth Stock for You?
Hims & Hers stock is trading based on speculation about its success with weight loss drugs. But that's a very small part of its business.
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
Novo Nordisk and Eli Lilly are currently the major players in the weight loss market. Hims & Hers Health is looking to disrupt the space by offering a lower-cost alternative.
Hims & Hers Health Boosts Outlook. Is This a Golden Opportunity to Buy the Stock?
Hims & Hers' revenue and profit metrics soared in the second quarter. Growth is expected to accelerate in the second half following the launch of the company's GLP-1 offering.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Stock Crashed but This Is a Growth Machine
Don't overlook the 52% growth in the second quarter.
Hims & Hers Health, Inc. (HIMS) Q2 2024 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Bill Newby - Head, IR Andrew Dudum - Co-Founder & CEO Yemi Okupe - CFO Conference Call Participants Maria Ripps - Canaccord Allen Lutz - Bank of America Jack Wallace - Guggenheim Securities Daniel Grosslight - Citi Jonna Kim - TD Cowen Aaron Kessler - Seaport Global Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Glen Santangelo - Jefferies George Hill - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers Second Quarter 2024 Earnings Conference Call.
Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago.
Shares of Hims & Hers, known for hair-loss treatments and Viagra, rally amid market panic
Shoppers might be spending less or seeking cheaper deals on takeout food and household items, and investors on Monday were panicking about the U.S. economy. But Hims & Hers Health Inc. — the online telehealth platform best known for selling hair-loss treatments, Viagra and Cialis — said customers are still piling in.
Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Got $200? 2 Best Growth Stocks to Buy and Hold Forever
Spending on healthcare and online purchases is rising even as consumer wallets remain constrained. Hims & Hers offers virtual care services and prescriptions through a simple recurring subscription plan.
Hims & Hers Health Stock Flashing Buy Signal Before Earnings
After a late-May bull gap on the charts, healthcare stock Hims & Hers Health Inc (NYSE:HIMS) steadily worked higher to snag a record high of $25.74 on June 18.
